Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crizanlizumab - Novartis

Next Previous
Drug Profile

Crizanlizumab - Novartis

Alternative Names: Adakveo; Crizanlizumab-tmca - Novartis; Ryverna; SEG-101; Sel G1

Latest Information Update: 06 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Selexys Pharmaceuticals
  • Developer Novartis
  • Class Antivirals; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Vaso-occlusive crisis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Vaso-occlusive crisis
  • Phase II Priapism; Vascular disorders
  • Phase I/II Myelofibrosis

Most Recent Events

  • 06 Jul 2025 Phase-II clinical trials in Vaso-occlusive-crisis (In children) (IV), Prior to July 2025 (Novartis pipeline, July 2025)
  • 07 Dec 2024 Updated efficacy and adverse event data from the phase II SOLACE-KIDS trial in Sickle cell disease presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 24 Oct 2024 Novartis initiates phase III SPARKLE trial for Vaso-occlusive-crisis (In adolescent, In adult, In the elderly) (IV, Infusion) in USA (NCT06439082)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top